12 Health Care Stocks Moving In Monday's Intraday Session
Why Arcus Biosciences's Stock is Up During Today's Session
Arcus Biosciences shares are trading higher. Not seeing any company-specific news to justify the price action.
BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10
Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti
Arcus Biosciences shares are trading lower after the company reported Q4 EPS and sales results down from last year.
Arcus Biosciences Is Maintained at Outperform by SVB Leerink
SVB Leerink Maintains Outperform on Arcus Biosciences, Lowers Price Target to $53
Arcus Biosciences analyst ratings
Arcus Biosciences Q4 EPS $(0.82) Down From $(0.38) YoY, Sales $9.49M Down From $9.75M YoY